Literature DB >> 22989750

Allele specific gain-of-function activity of p53 mutants in lung cancer cells.

Catherine A Vaughan1, Rebecca Frum, Isabella Pearsall, Shilpa Singh, Brad Windle, Andrew Yeudall, Swati P Deb, Sumitra Deb.   

Abstract

p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53. Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate. Two lung cancer cell lines, ABC1 and H1437, carrying endogenous mutants p53-P278S and -R267P, show reduction in growth rate on knock-down on p53 levels. However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells. We have tested their transactivation potential on p53 target gene promoters by performing transient transcriptional assays in the p53-null H1299 lung cancer cell line. Interestingly, while the mutant p53 target promoter Axl was activated by both the mutants, the p21 promoter was activated by p53-R267P and wild-type p53 but not by p53-P278S; showing a clear difference in transcriptional activity between the two mutants. Our results demonstrate allele specificity between GOF p53 mutants and attempt to show that the specificity is dependent on the transactivation property of GOF p53; it also suggests importance of p21 activation in tumor suppression by p53.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22989750      PMCID: PMC4731231          DOI: 10.1016/j.bbrc.2012.09.029

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective.

Authors:  C C Harris
Journal:  Carcinogenesis       Date:  1996-06       Impact factor: 4.944

Review 2.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

3.  p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.

Authors:  S L Lai; R P Perng; J Hwang
Journal:  J Biomed Sci       Date:  2000 Jan-Feb       Impact factor: 8.410

4.  A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model.

Authors:  K L Murphy; A P Dennis; J M Rosen
Journal:  FASEB J       Date:  2000-11       Impact factor: 5.191

5.  Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination.

Authors:  W R Taylor; S E Egan; M Mowat; A H Greenberg; J A Wright
Journal:  Oncogene       Date:  1992-07       Impact factor: 9.867

6.  Modulation of gene expression by tumor-derived p53 mutants.

Authors:  Mariano J Scian; Katherine E R Stagliano; Michelle A Ellis; Sajida Hassan; Melissa Bowman; Michael F Miles; Swati Palit Deb; Sumitra Deb
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

Review 7.  The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

Authors:  C Cadwell; G P Zambetti
Journal:  Gene       Date:  2001-10-17       Impact factor: 3.688

Review 8.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

9.  Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.

Authors:  J Lin; A K Teresky; A J Levine
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

Review 10.  The p53/p63/p73 family of transcription factors: overlapping and distinct functions.

Authors:  M Levrero; V De Laurenzi; A Costanzo; J Gong; J Y Wang; G Melino
Journal:  J Cell Sci       Date:  2000-05       Impact factor: 5.285

View more
  13 in total

1.  Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.

Authors:  Chang Xu; Olga Nikolova; Ryan S Basom; Ryan M Mitchell; Reid Shaw; Russell D Moser; Heuijoon Park; Kay E Gurley; Michael C Kao; Carlos L Green; Franz X Schaub; Robert L Diaz; Hallie A Swan; In S Jang; Justin Guinney; Vijayakrishna K Gadi; Adam A Margolin; Carla Grandori; Christopher J Kemp; Eduardo Méndez
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

2.  Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.

Authors:  Shilpa Singh; Catherine A Vaughan; Rebecca A Frum; Steven R Grossman; Sumitra Deb; Swati Palit Deb
Journal:  J Clin Invest       Date:  2017-04-10       Impact factor: 14.808

3.  A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.

Authors:  Alice Soragni; Deanna M Janzen; Lisa M Johnson; Anne G Lindgren; Anh Thai-Quynh Nguyen; Ekaterina Tiourin; Angela B Soriaga; Jing Lu; Lin Jiang; Kym F Faull; Matteo Pellegrini; Sanaz Memarzadeh; David S Eisenberg
Journal:  Cancer Cell       Date:  2015-12-31       Impact factor: 31.743

4.  Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib.

Authors:  Shengzhi Xie; Yongwu Li; Xiaoyan Li; Linxiong Wang; Na Yang; Yadi Wang; Huafeng Wei
Journal:  Oncotarget       Date:  2015-04-20

Review 5.  Axl as a mediator of cellular growth and survival.

Authors:  Haley Axelrod; Kenneth J Pienta
Journal:  Oncotarget       Date:  2014-10-15

6.  Effect of the p53α gene on the chemosensitivity of the H1299 human lung adenocarcinoma cell line.

Authors:  Kaishan Liu; Weisong Gao; Jun Lin
Journal:  Oncol Lett       Date:  2017-06-08       Impact factor: 2.967

7.  Gain-of-function p53 activates multiple signaling pathways to induce oncogenicity in lung cancer cells.

Authors:  Catherine A Vaughan; Shilpa Singh; Steven R Grossman; Brad Windle; Swati Palit Deb; Sumitra Deb
Journal:  Mol Oncol       Date:  2017-05-08       Impact factor: 6.603

8.  Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.

Authors:  Qi Fei; Ke Shang; Jianhua Zhang; Shannon Chuai; Desheng Kong; Tianlun Zhou; Shijun Fu; Ying Liang; Chong Li; Zhi Chen; Yuan Zhao; Zhengtian Yu; Zheng Huang; Min Hu; Haiyan Ying; Zhui Chen; Yun Zhang; Feng Xing; Jidong Zhu; Haiyan Xu; Kehao Zhao; Chris Lu; Peter Atadja; Zhi-Xiong Xiao; En Li; Jianyong Shou
Journal:  Nat Commun       Date:  2015-10-16       Impact factor: 14.919

9.  More targets, more pathways and more clues for mutant p53.

Authors:  S Garritano; A Inga; F Gemignani; S Landi
Journal:  Oncogenesis       Date:  2013-07-01       Impact factor: 7.485

Review 10.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.